Recommendations for streamlining precision medicine in breast cancer care in Latin America.
CDx
Latin America
breast cancer
companion diagnostics
precision medicine
Journal
Cancer reports (Hoboken, N.J.)
ISSN: 2573-8348
Titre abrégé: Cancer Rep (Hoboken)
Pays: United States
ID NLM: 101747728
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
revised:
27
03
2021
received:
21
02
2021
accepted:
30
03
2021
pubmed:
4
5
2021
medline:
8
3
2022
entrez:
3
5
2021
Statut:
ppublish
Résumé
The incidence of breast cancer (BC) in LMICs has increased by more than 20% within the last decade. In areas such as Latin America (LA), addressing BC at national levels evoke discussions surrounding fragmented care, limited resources, and regulatory barriers. Precision Medicine (PM), specifically companion diagnostics (CDx), links disease diagnosis and treatment for better patient outcomes. Thus, its application may aid in overcoming these barriers. A panel of LA experts in fields related to BC and PM were provided with a series of relevant questions to address prior to a multi-day conference. Within this conference, each narrative was edited by the entire group, through numerous rounds of discussion until a consensus was achieved. The panel proposes specific, realistic recommendations for implementing CDx in BC in LA and other LMIC regions. In these recommendations, the authors strived to address all barriers to the widespread use and access mentioned previously within this manuscript. This manuscript provides a review of the current state of CDx for BC in LA. Of most importance, the panel proposes practical and actionable recommendations for the implementation of CDx throughout the Region in order to identify the right patient at the right time for the right treatment.
Sections du résumé
BACKGROUND
The incidence of breast cancer (BC) in LMICs has increased by more than 20% within the last decade. In areas such as Latin America (LA), addressing BC at national levels evoke discussions surrounding fragmented care, limited resources, and regulatory barriers. Precision Medicine (PM), specifically companion diagnostics (CDx), links disease diagnosis and treatment for better patient outcomes. Thus, its application may aid in overcoming these barriers.
RECENT FINDINGS
A panel of LA experts in fields related to BC and PM were provided with a series of relevant questions to address prior to a multi-day conference. Within this conference, each narrative was edited by the entire group, through numerous rounds of discussion until a consensus was achieved. The panel proposes specific, realistic recommendations for implementing CDx in BC in LA and other LMIC regions. In these recommendations, the authors strived to address all barriers to the widespread use and access mentioned previously within this manuscript.
CONCLUSION
This manuscript provides a review of the current state of CDx for BC in LA. Of most importance, the panel proposes practical and actionable recommendations for the implementation of CDx throughout the Region in order to identify the right patient at the right time for the right treatment.
Identifiants
pubmed: 33939336
doi: 10.1002/cnr2.1400
pmc: PMC8714537
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1400Subventions
Organisme : Health Foundation
Informations de copyright
© 2021 The Authors. Cancer Reports published by Wiley Periodicals LLC.
Références
Biologics. 2007 Mar;1(1):19-31
pubmed: 19707345
N Engl J Med. 2018 Nov 29;379(22):2108-2121
pubmed: 30345906
J Clin Oncol. 2013 Nov 1;31(31):3997-4013
pubmed: 24101045
Rev Peru Med Exp Salud Publica. 2011 Jun;28(2):177-85
pubmed: 21845296
Cancer. 2015 Jul 1;121(13):2198-206
pubmed: 25809536
Salud Publica Mex. 2014 Sep-Oct;56(5):547-54
pubmed: 25604300
Arch Pathol Lab Med. 2020 May;144(5):545-563
pubmed: 31928354
Arch Pathol Lab Med. 2018 Nov;142(11):1364-1382
pubmed: 29846104
Cancer Epidemiol. 2016 Sep;44 Suppl 1:S110-S120
pubmed: 27678313
Science. 1987 Jan 9;235(4785):177-82
pubmed: 3798106
Lancet Oncol. 2011 Apr;12(4):387-98
pubmed: 21463833
Cancer Rep (Hoboken). 2021 Dec;4(6):e1400
pubmed: 33939336
Lancet Oncol. 2016 Aug;17(8):e363-e370
pubmed: 27511160
PLoS One. 2019 Oct 16;14(10):e0224012
pubmed: 31618268
Nat Commun. 2016 May 10;7:11479
pubmed: 27161491
Lancet. 2017 Feb 25;389(10071):847-860
pubmed: 27814965
Public Health Genomics. 2019;22(1-2):8-15
pubmed: 31330522
Cancer Manag Res. 2018 Apr 12;10:745-753
pubmed: 29695931
J Clin Oncol. 2006 Aug 10;24(23):3726-34
pubmed: 16720680
Oncologist. 2018 Apr;23(4):440-453
pubmed: 29284758
Am J Cancer Res. 2020 May 01;10(5):1568-1591
pubmed: 32509398
Virchows Arch. 2019 Aug;475(2):191-199
pubmed: 31264038
Mod Pathol. 2012 Aug;25(8):1098-105
pubmed: 22460807
Eur J Cancer. 2017 Feb;72:244-250
pubmed: 28064097
Br J Cancer. 2015 Mar 31;112 Suppl 1:S92-107
pubmed: 25734382
J Histochem Cytochem. 2002 Dec;50(12):1693-6
pubmed: 12486093
Oncologist. 2019 Dec;24(12):e1371-e1380
pubmed: 31387949
Front Oncol. 2014 May 16;4:105
pubmed: 24904822
Cancer Epidemiol Biomarkers Prev. 2006 Jan;15(1):45-51
pubmed: 16434585
Ann Intern Med. 2002 Sep 3;137(5 Part 1):347-60
pubmed: 12204020
Soc Sci Med. 2009 Mar;68(6):1153-60
pubmed: 19178990
Clin Lab Med. 2018 Mar;38(1):161-173
pubmed: 29412880
BMC Public Health. 2020 May 1;20(1):603
pubmed: 32357943
J Clin Oncol. 2009 Mar 10;27(8):1160-7
pubmed: 19204204
Am J Surg Pathol. 2011 Apr;35(4):545-52
pubmed: 21358301
Breast Cancer (Auckl). 2018 Jan 08;12:1178223417752677
pubmed: 29434475
Oncologist. 2013;18(3):248-56
pubmed: 23442305
Sci Rep. 2020 Apr 27;10(1):7029
pubmed: 32341397
BMC Cancer. 2014 Mar 13;14:177
pubmed: 24625003
JAMA. 2014 Apr 2;311(13):1327-35
pubmed: 24691608
Breast. 2013 Aug;22 Suppl 2:S152-5
pubmed: 24074778
N Z Med J. 2004 May 07;117(1193):U869
pubmed: 15133519
Pharmgenomics Pers Med. 2016 Jan 22;9:7-16
pubmed: 26858530
J Oncol. 2010;2010:490631
pubmed: 21209708
Mod Pathol. 2013 Apr;26(4):607-9
pubmed: 23542522
Am Surg. 2018 Nov 1;84(11):1787-1789
pubmed: 30747634
Rev Panam Salud Publica. 2002 Mar;11(3):178-85
pubmed: 11998184
Future Oncol. 2014 Oct;10(12):1953-65
pubmed: 25386812
Am J Pathol. 2017 Oct;187(10):2185-2198
pubmed: 28733195
Public Health Genomics. 2017;20(3):194-201
pubmed: 28848219
Expert Rev Precis Med Drug Dev. 2018 Jan 08;3(1):1-9
pubmed: 29682615
N Engl J Med. 2002 Dec 19;347(25):1999-2009
pubmed: 12490681
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Clin Oncol. 2010 Jun 1;28(16):2784-95
pubmed: 20404251
Cancer. 2011 Dec 15;117(24):5461-8
pubmed: 21681735
World J Clin Oncol. 2014 Aug 10;5(3):465-77
pubmed: 25114860